News and Articles on Health. Medical research topics.

The article reported the overall average of the baseline and post treatment nitric oxide levels; the individual results of each of the 23 participants were not included.

Although pain and function were not measured, most participants reported an enhanced relaxation response after treatment.

The cranial therapy was associated with changes in NO levels in exhaled breath. The level of NO increased from 13.3 +/- 2.09 (SD) to 15.0 +/- 2.95 (SD) ppb (P=0.001, based upon the paired t tests of the subjects). The median level of NO before the cranial therapy was 13.0 ppb (ranging from 8 to 17 ppb); after cranial therapy, it was 16.0 ppb (ranging from 6 to 18 ppb).

Although pain and function were not measured, most participants reported an enhanced relaxation response after treatment; the most relaxed participants were those with the highest post-treatment exhaled NO levels.

Practice Implications
This study is the first to explore the physiological effect of cranial therapy on NO production. These finding are significant, especially since we are increasingly learning of the important role that NO plays in various aspects of health. It is also a big step for the cranial community, because despite having a long, rich history and an immense archive of anecdotal evidence, cranial therapy lacks substantial clinical research studies. Currently an explanation of how cranial therapy can produce an increase in exhaled NO levels remains theoretical.

Traditionally, elevated exhaled NO levels have been closely associated with chronic pulmonary conditions such as asthma. This is why it was so vital to choose participants who were qualified as “healthy adults.” Since there were no asthmatic participants, and those with post-treatment elevated levels of NO reported an enhanced relaxation response, I would hypothesize that there is an intimate connection between naturally increasing the body’s ability to produce NO and being able to decrease the devastating effects that stress has on the body. The article also states that this therapy could be a key adjunct in the prevention of coronary artery disease (CAD) and diabetes—both of which damage epithelial lining of blood vessels (indicative of low NO production). When lowered NO levels allow damage to the blood vessels to occur, the endothelium is less able to produce the necessary amount of NO, thus facilitating further endothelial damage. This, over time, can manifest into serious pathological conditions. Given the noninvasive nature of the procedure, this cranial therapy could potentially be an incredible asset to those treating such conditions.

Since the 1990s, NO has been aggressively studied—its relationship to cardiovascular health only discovered in 1998—and it has been found that too little NO, as seen in CAD and diabetic cases, can have a damaging effect, but too much can also be detrimental. In the instance of an excess of NO, further research to examine whether this cranial maneuver may have a modulating effect on NO levels would be interesting, as colleagues in the cranial field have reported positive results with asthmatic patients.

Although this study is small and uncontrolled, which is not typically the type of study highlighted in this column, these findings are relevant to clinical practice. NO is, as we’ve seen, a critical component in maintaining health. In the clinical field, NO and its precursors are being utilized in a variety of ways, ranging from treatment of pulmonary vascular disease in pediatrics, to pain associated with angina, to erectile dysfunction. It’s also becoming a staple for preventative and anti-aging protocols.

We’ve long known that there are noninvasive, effective methods of increasing NO levels, whether through supplementing with arginine or even regular exercise, but until now there has not been a physical modality that has shown a possible systemic increase in NO. These findings also suggest that various healthcare providers and readers of this column may, in addition to their current prevention or treatment protocols, begin to incorporate this type of cranial therapy into their practice.

Main Outcome Measures
Various outcome data were collected, including length of hospitalization, need for postoperative analgesics, routine vital signs, and patient ratings of pain intensity and distress as well as anxiety and fatigue. Validated assessment metrics included the State-Trait anxiety Inventory Form Y-1, the Environmental Assessment Scale, and the Patient’s Room Satisfaction Questionnaire.

Key Findings
Post-study evaluation of data revealed that patients assigned to recovery rooms with foliage demonstrated significantly lower systolic blood pressure, perception of postoperative pain, anxiety, and fatigue than those in the control group. Validated surveys also revealed subjective increase in satisfaction with their assigned room, stating that the plants brightened the environment, reduced stress, and evoked more positive impressions of hospital employees engaged in their care.

Practice Implications
The true beauty of this study lies in its simplicity and elegance, reflective of nature itself. The investigators chose to evaluate postoperative pain after a common surgical procedure, and the intervention chosen was inexpensive, nontoxic, and required no randomized controlled trial or FDA approval prior to utilization.
Given the current clinical and fiscal need for alternatives to our conventional approach to pain management, this simple intervention holds promise as adjunctive analgesia for simple surgical procedures.
Given the current clinical and fiscal need for alternatives to our conventional approach to pain management, this simple intervention holds promise as adjunctive analgesia for simple surgical procedures.

This is not the first attempt to utilize the hospital environment as therapeutic modality. Architects and contractors across this country and abroad have been engaged in a revolutionary movement to redesign hospital buildings both inside and out, with more than 1,500 studies to date demonstrating that architectural design significantly influences rates of medical errors, clinical infections, accidental falls, and levels of stress in both patient and staff. As one example, researchers have documented that the simple addition of sunlight to a hospital room is associated with improvement in mood and affect, diminished mortality in cancer patients, reduced length of stay in patients with myocardial infarctions, and decreased analgesic use and costs after spinal surgery. The Center for Health Design, a non-profit based in California, has created the Pebble Project, a partnership of 44 hospitals to investigate the clinical and fiscal benefits of intelligent building design. Their data reveal lower noise levels, improved patient sleep, decreased staff turnover, reduced medication requirements, and declining drug errors. Given that the majority of our pharmaceutical medications have been extracted from living botanicals, it is poignant to consider that the original plant may prove a superior therapy in the long run. Future studies should be done to confirm this study’s findings and delineate what aspect of the live plant (eg, visual, olfactory, qi) might be responsible for improved outcomes.

“Both unadjusted tests and linear regression models indicated that CAM users had lower average expenditures than nonusers. (Unadjusted: $3,79β7 versus $4,153, P=.0001; β from linear regression -$367 for CAM users.) CAM users had higher outpatient expenditures that which were offset by lower inpatient and imaging expenditures. The largest difference was seen in the patients with the heaviest disease burdens among whom CAM users averaged $1,420 less than nonusers, P<0.0001, which more than offset slightly higher average expenditures of $158 among CAM users with lower disease burdens.”

Practice Implications
This paper is the latest in a series from this team to evaluate insurance claims databases resulting after a 1996 insurance inclusion mandate for CAM providers in Washington state. The change in regulation required that health insurance companies operating within the state to provide access to every state-qualified class of healthcare providers. Earlier papers from the group found that overall claims were little affected by coverage of CAM providers due to smaller claim size compared to conventional medical claims. Those studies also found that CAM users tended to have higher morbidity than non-users.

Cost studies are few in CAM research. Cost minimization, the approach of this paper, analyzes which of 2 approaches to care is associated with lower overall expenditures, assuming comparable health outcomes between the two approaches. “CAM users” were those who had made claims for visiting any of the following CAM providers: acupuncturists, chiropractors, massage therapists, and naturopathic physicians. Average claims costs in this analysis were about 9% lower over 1 year among CAM users than non-users, showing lower inpatient and ancillary costs (e.g., imaging, laboratory) but higher outpatient visit costs.

The cost outcomes, while favorable to CAM provider use, are associated with and not demonstrably caused by CAM provider visits reflected in the claims. The smaller costs among CAM users may be generated by other health and lifestyle factors associated with going to CAM practitioners (e.g., newly acquired patient activation in the face of a chronic problem, surrendering conventional medical interventions due to therapeutic failures).

Though coverage of CAM providers was made available, coverage was generally not equal to coverage of conventional providers, being restricted among different insurance companies by limits to the number of CAM visits, to a specified network of a providers, or to an overall CAM costs cap.
Not all CAM care costs are included in the data set; for example, dietary supplements, which may be a necessary part of CAM treatment, are typically not covered even if provider visits are.
Not all CAM care costs are included in the data set; for example, dietary supplements, which may be a necessary part of CAM treatment, are typically not covered even if provider visits are. The analysis was done in three impactful conditions—back pain, fibromyalgia, and menopausal symptoms—which all have somewhat uncertain etiologies. They are also conditions that are often refractory to conventional treatment, so findings again may not be generalized to all conditions. These conditions fall into the emerging research area of medically unexplained physical syndromes (MUPS), in which the lowest hanging fruit for CAM research targets may be found.

To answer the question of causation requires prospective intervention studies; however, matching patients in the comparison groups of users versus non-users on the basis of their total medical claims in the year prior to initiating CAM claims makes this study suggestive of a generalizable finding in future economic analyses. Patients without a year of claims prior to initiating CAM claims were not included in analysis.

Different providers types were not distinguished in the analysis on the basis that there were too few claims for any 1 provider type for valid interpretation of the data by discipline (personal communication with first author). The study thus provides little guidance to consumers in choosing a provider, but more confidence that doing something alternative may be a good choice. Claims costs in only 1 year were evaluated; savings from CAM use may come with prevention, and thus subsequent savings could not be addressed. The study did not include Medicaid, Medicare, or state program–covered patients—populations that may be more susceptible to improvement under CAM care due to historical lack of access to it.

Despite its limitations, this creative use of existing data provides some evidence that costs of CAM providers are not redundant to conventional care and that CAM provider use may well be cost-saving. As more such data has become available with increasing inclusion and longevity of CAM providers in insurance coverage over the last decade, replication of this study in other regions and conditions is increasingly possible and should be performed.

GSH is one of the most extensively studied chemicals of the human body and its decline with aging and disease risk is well established. GSH is needed both for maintenance of normal metabolism and for defense against a range of disease and toxicity mechanisms. GSH is maintained by continuous processes of GSSG reduction and GSH transport, degradation, and synthesis. GSH concentrations are considerably higher in tissues than in most body fluids, but the fluid concentrations are important because they protect cell surfaces and support protective barrier defenses. Extensive research in model systems establishes that GSH is transported by cells and that added GSH protects against a range of chemical and infectious threats. Although most Americans consume an adequate supply of dietary precursors for GSH synthesis, there is a gap between the amount synthesized and the amount needed (ie, a decline in GSH is associated with disease risk). Based upon the loss of GSH from food during processing and the measured contents of reactive chemicals in food, this gap can be estimated to be 300 mg/day. However, higher values may be needed to compensate for adverse environmental conditions and disease, but the possible amounts can only be speculated.
malegra
Because the American healthcare system is approaching crisis with the ballooning costs of late-stage disease treatment, cost-effective means are needed to preserve health. Available (but not FDA-approved) methods allow prospective assessment of GSH in individuals prior to disease onset, and health maintenance programs are beginning to adopt GSH analysis as part of quantitative health assessment (but not disease treatment). Simple strategies, including supply of GSH, GSH precursors, complementary antioxidants, and zinc, are available to improve GSH status in individuals with low or oxidized GSH. Such strategies could have considerable personal and societal health and economic impact.

Consequently, the scientific evidence supports the conclusion that the body can utilize exogenously supplied GSH. This characteristic is identical to some vitamins (eg, niacin), amino acids (eg, histidine), and amino sugars (eg, glucosamine), which are utilized from the diet even though they are synthesized within the body. For these, a nutritional deficiency can develop when the amount synthesized is insufficient to fulfill requirements. While GSH is not considered a required nutrient, the same principles apply (ie, a deficiency can develop when the amount of GSH synthesized is insufficient for detoxification needs).

GSH concentration and GSH/GSSG redox balance can be measured in human plasma, and this provides a means to identify individuals with poor GSH status. Plasma GSH levels decrease with age beginning at about 45 y, undergo a diurnal variation with lowest values at midday and are decreased and oxidized in association with disease risk and disease. However, despite the general utility of plasma measurements, deficiencies at barrier surfaces, such as the intestines, lung lining fluid, and immune cells associated with these surfaces, may not be apparent from plasma measurements. This leaves a dilemma in that at least some of the sites most likely to benefit from supplemental GSH are relatively inaccessible for measurement.

The Future: The Health Dividend of GSH

GSH supplementation can be implemented in individuals based upon their known risk factors, but validation that such strategies are effective in humans will require lengthy and costly controlled double-blind studies. In the meantime, validated methods are available to measure GSH and GSSG in body fluids but have not yet been approved by the Food and Drug Adminstration for clinical use. Availability of such measurements would provide means to evaluate health in individuals and to directly evaluate the efficacy of interventional strategies to normalize GSH and GSH redox balance in individuals with low values. Recent studies show that a related cysteine (Cys) redox balance for plasma cysteine and cystine is more directly related to extracellular oxidative processes and is associated with cardiovascular risk. Analyses of GSH redox and Cys redox have been performed in long-term interventional trials with free radical-scavenging antioxidants (vitamins C, E;) and also zinc in age-related macular degeneration. Results show that GSH redox balance and/or the Cys redox balance is preserved in association with protection against disease progression. Zinc has been found to activate mechanisms for GSH synthesis and also stimulate uptake of cystine. Consequently, combinations of GSH, GSH precursors (including preparations such as whey protein isolates), antioxidants, and inducers of transport and synthesis may provide complementary means to enhance GSH status.

GSH Support Strategies: How Can We Improve GSH Status?

GSH is synthesized from amino acid precursors, glutamate, cysteine and glycine. A considerable number of trials have used N-acetylcysteine (NAC) as a cysteine precursor, expecting it to provide a means to increase GSH synthesis. The logic for using NAC is complicated but generally assumes that cysteine is limiting for GSH synthesis. However, the American diet typically has an excess of sulfur amino acids. According to NHANES III, 99% of adult American males and females consume greater than the RDA, 50% consume more than twice the RDA and 1% of people consume more than 4 times the RDA for sulfur amino acids. Consequently, while NAC is likely to benefit individuals with insufficient sulfur amino acid intake, additional approaches are needed to address a functional need for GSH in most Americans. Supplementation with glutamate, cysteine, and glycine provides one alternative, and others include related sources of these amino acids (eg, whey), supplements to enhance synthesis (eg, silymarin), as well as the naturally occurring compound itself, GSH.

A common assumption is that dietary or supplemental GSH is not available for use by the human body because the intestines contain an enzyme (ie, γ-glutamyl transpeptidase; GGT) that degrades GSH. However, a substantial amount of scientific evidence shows that supplemental GSH is bioavailable. As indicated above, added GSH supports detoxification in body fluids such as the lining fluid of the lung and intestines, enhances macrophage function, and decreases influenza virus production. Thus, even for cells that do not absorb GSH, protection can be provided by supplemental GSH.

Different research groups have also shown that GSH is transported across intestinal membranes, across the intestinal epithelium, into human intestinal cells, and from the intestinal lumen into the vascular circulation. Orally administered GSH increases GSH in mouse, rat, and human plasma, and the extent of increase is increased by a stress response. While studies are not universally consistent, and most organs do not take up GSH, experiments with isotopic tracers, inhibitors of GSH synthesis, inhibitors of GSH transport, and inhibitors of GSH degradation provide detailed evidence for GSH transport in intestines, lung, and kidneys. This subject has been recently reviewed by Lawrence Lash, and this should be consulted for additional details. Animal and human studies further show direct benefit of oral GSH in protection against age-related decline in immune function; enhancement of lymphocyte function; and protection against oxidative injury in newborn lung, influenza viral infection, chemically induced oral cancer, and uptake of peroxidized lipids and other toxic chemicals.

Because of the known functions and increased disease risk with a decline of GSH, systematic efforts are needed to quantify the difference between the available GSH and the amount needed. One approach is to consider how much GSH is present in a natural diet. GSH content has been measured in more than 100 common foods37 and provides the basis to estimate dietary intake. The best diets contain about 150 milligrams of GSH per day; the worst diets contain as little as 3 milligrams per day. GSH is present in essentially all raw and freshly prepared foods; the best sources are fresh fruits and vegetables, nuts, and whole-cut meats, including poultry and fish. GSH can also be increased by supplements, such as the increase in hepatic GSH following ingestion of silymarin, found in milk thistle. GSH is lost during most food processing procedures, with the exception of fresh-frozen foods. Processed, cured, and canned meat products have essentially no GSH. Similarly, canned or dried fruits and canned vegetables are not good sources. Cereal and grain products are largely deficient, and almost all dairy products, beverages, sweeteners, and condiments lack GSH. Thus, a simple conclusion is that modern processed foods are deficient in GSH compared to natural, freshly prepared foods. In quantitative terms, up to 150 mg of daily intake of GSH can be lost due to food processing.

Many foods also contain reactive chemicals that remove GSH through the GSH transferase reaction associated with the lining of the small intestines. Measurement of a broad range of foods show that milk, prunes, tea, blueberries, and bottled apple juice have high contents of GSH-reactive chemicals.38 Recently, there has been interest in the potent neurotoxicant acrylamide, because this has been found to be relatively high in french fries. The daily intake of GSH-reactive equivalents can range from almost zero to values exceeding the maximum naturally available 150 milligrams GSH.38 Thus, the sum of the amount of GSH needed to eliminate reactive chemicals and the amount of GSH lost by food processing can be greater than 300 mg of GSH per day.

Measurement of a broad range of foods show that milk, prunes, tea, blueberries, and bottled apple juice have high contents of GSH-reactive chemicals.

The extent to which environmental exposures, alcohol consumption, smoking, inflammation, infection, etc., further increases this dietary GSH gap is not known. Similarly, the magnitude of the GSH gap due to disease is not known. This could be greater than 300 mg—perhaps as high as the GSH equivalent of the RDA for sulfur amino acids (ie, 3 g/day). The RDA for sulfur amino acids is about 1.1 g/day for women and 1.4 g/day for men; these values are equivalent to 2.7 and 3.3 g/day of GSH. Because the body contains 15 g of GSH, values in this range represent up to 20% of the amount of GSH in the body. There are conditions, such as severe burns, in which the sulfur amino acid requirement is increased. Consequently, there may be conditions in which the functional need for GSH is relatively high, but this upper limit is currently unknown.

GSH is depleted by elimination of reactive chemicals dependent upon abundant GSH transferases. These enzymes increase in response to toxic challenge, and trials have been conducted to determine whether continuous elevation of these enzymes can protect against cancer. In protection against cancer, GSH reacts with cancer-causing chemicals at rates that are faster than the chemical can react with DNA, thereby preventing mutations. To date, however, practical approaches to reduce cancer by increasing GSH transferase have not been established. In addition to cellular activities, GSH transferase is associated with mucus and provides a detoxifying barrier in the small intestines. Animal studies showed that provision of GSH to the GSH transferase associated with the mucus provides a defense mechanism to eliminate ingested toxic chemicals, such as oxidation products from polyunsaturated fatty acids, acrylein, acrylamide, and other reactive chemicals, prior to absorption by the body. This defense depends upon GSH supply outside of the cells, either from the bile, from food, or from a supplement. The finding that oral and pharyngeal cancer is decreased in association with intake of foods high in GSH25 could reflect the function of this mechanism in protection against cancer-causing chemicals or a better function of the immune system. Studies with human cells in culture further show that added GSH protects cells even in the absence of GSH uptake, apparently due to protection of proteins on the surface of cells. Recent studies show that cell surface thiols function as redox sensors, signaling processes such as platelet activation and early events of atherosclerosis. As indicated above, in vitro experiments have demonstrated that addition of GSH to the media improved killing of bacteria by pulmonary macrophages and decreased production of infectious influenza virus by human small airway epithelial cells.

How Big is the Functional Need for GSH?

In addition to the age-related decline mentioned above, GSH levels are inversely associated with environmental exposures and disease risk. GSH is decreased in the epithelial lining fluid of human lung in individuals who abuse alcohol. This example is illustrative of the hidden risks of low GSH in that these individuals have no apparent lung disease and yet are at considerably increased risk of acute lung injury and death from adult respiratory death syndrome. Oxidation of GSH occurs in association with increased carotid intima media thickness, an indicator of cardiovascular disease risk. GSH redox balance (ie, the GSH/ GSSG ratio) favors oxidation in cigarette smokers and type 2 diabetics. Direct evidence that the decrease and oxidation of GSH occurs due to toxic chemical exposures is available from studies in individuals following chemotherapy. The extensive evidence that GSH status is decreased in association with disease and recognized risk factors for disease implies that maintenance of this protective system could reduce risk of disease development.

Homeostatic mechanisms prevent the hepatic GSH content from falling too low. During fasting and starvation, GSH and its precursors are derived from muscle and other tissues. Simple calculations show that the entire human body has no more than a 4-day reserve of GSH so that loss of GSH can become critical in catabolic illness or whenever there is a prolonged period of protein/energy insufficiency. Importantly, GSH declines with age and has a diurnal variation with lowest values in the morning and early afternoon. The diurnal variation is linked to cysteine, and cysteine variation increases in individuals over 60 years. Thus, older individuals have increased vulnerability in cell injury due to both a decline in total amount of GSH and a decline in its homeostatic control.

Most research has focused on tissue levels of GSH, but the difference between GSH needs and availability may be equally important in the extracellular fluids, which bathe cells. GSH is found in all extracellular biological fluids, including plasma, interstitial fluid, cerebrospinal fluid, alveolar lining fluid, saliva, bile, pancreatic fluid, tears, sweat. and urine. The concentration of GSH in body fluids can be up to 1,000-fold lower than found in the tissues, yet all cells appear to release GSH, suggesting a universal requirement for extracellular GSH to protect cell surfaces. In addition, specific functions of extracellular GSH are well described. Bile has a high content of GSH to support detoxification of reactive chemicals in the lumen of the small intestines and to enhance iron absorption. Lipid peroxides are toxic species in the diet that are eliminated by supplemental GSH. GSH in the lining fluid of the lungs eliminates airborne oxidants and helps maintain fluidity of the mucus lining the airways. Elimination of bacteria by pulmonary macrophages in vitro is stimulated by added GSH, but this experiment has not been done in humans in vivo. GSH also protects human lung cells (in vitro) from influenza virus and protects against influenza in mice. One should note that controlled, double-blind studies of these effects have not been done in vivo in humans.

How is GSH Maintained in Tissues and Body Fluids?

GSH is maintained by a continuous cycle of turnover at a rate equivalent to the entire body pool of GSH being made and degraded daily. GSH is synthesized from the precursor amino acids (ie, glutamine, glycine, cysteine) in all tissues. Cells in certain organs (ie, intestines, lung, kidney) can utilize exogenous GSH by a secondary active transport mechanism. Supply of GSH from tissue to extracellular fluids occurs through two types of transporters, classified as MRP and OAT transport proteins. The molecular nature of the systems that allow transport in the opposite direction (from extracellular spaces into cells) is not known. The cycle of GSH release, conversion to precursor amino acids, and resynthesis is termed the “GSH cycle.” Although it was earlier proposed that a “γ-glutamyl cycle” functioned in amino acid uptake, this was found to not be an important mechanism. Disulfide forms of GSH include low molecular weight chemicals and protein-bound forms; under many circumstances, the balance between GSH and these disulfide forms (ie, GSH redox balance) can be more important than the absolute amount of GSH.

GSH is a simple molecule, composed of 3 common amino acids: glutamate, cysteine, and glycine, which are also found in protein throughout the body. The amino acids are connected in a unique way so that GSH can be made and broken down independently of the body’s protein. The structure controls the reactivity of a sulfur atom in the cysteine, which is critical for function. GSH reacts with toxic oxygen radicals to form GSH radicals and glutathione disulfide (GSSG), thereby protecting against oxidative damage to DNA and proteins. Living organisms depend on controlled reactions in which chemicals share and transfer electrons to maintain physical and chemical organization. Reactive chemicals with a high affinity for electrons destroy the organization and function because they interfere with the normal processes of sharing and donating electrons. The body is constantly exposed to damaging reactive chemicals, and GSH provides a general biological solution because the electron properties of the sulfur of GSH are ideally suited to protect against such chemicals.

In protection against an imbalance in electron transfer reactions, termed “oxidative stress,” GSH donates electrons to chemicals known as “oxidants.” Oxidants avidly accept electrons, and this disrupts normal electron flow. The electron-donating property of GSH protects against this; in the process, two molecules of GSH are converted to GSSG, an oxidized (disulfide) form. The balance of GSH and GSSG is quantified as the “GSH redox balance,” a measure of the status of the GSH system to protect against such oxidative challenges. In this expression, more reduced (more negative) “redox” values are generally healthy, while more oxidized (more positive) “redox” values are unhealthy. Values measured in blood are a reflection of tissue values because cells have transport systems for both GSH and GSSG. However, oxidation also occurs outside of cells, so under a normal, healthy state, the extracellular balance is oxidized relative to that in cells. Many diseased states have excessively oxidized extracellular GSH redox values.
Canadian generic viagra
Where is GSH found in the body?
GSH is found in all tissues and body fluids. A healthy balance requires an unequal distribution of GSH and GSSG among these locations,6 similar to the need for sodium and potassium to differ between plasma and cells. In general, the concentrations of GSH within cells are much higher than outside of cells. Nonetheless, the amounts of GSH in the fluids surrounding cells are important because they provide a chemical-defense barrier to protect the cell surfaces.

The total amount of GSH in the body is about 15 grams, of which the cysteine component represents 5 grams. The organs principally responsible for detoxification (ie, the liver and kidneys), have the highest amounts, but the 15 grams are distributed among all major organ systems, including brain, heart, skeletal muscle, intestines, lungs, skin, and the immune system. The liver (6% of the body) has about 4 grams of GSH (25% of the body’s total), which is part of an important homeostatic mechanism. Liver GSH varies as a function of diet, time of day, and body needs. The cysteine content of liver GSH is similar to the RDA for sulfur amino acids (methionine plus cysteine), which is 1.4 g for a reference 70 kg individual. Thus, the GSH in the liver is equivalent to a 1-day reserve for the cysteine needed for the body’s protein synthesis.

Abstract
Glutathione (GSH) is a naturally occurring chemical used by the human body to protect against chemical and environmental threats. As a consequence of aging, lifestyle, diet, and disease, a gap can develop between the needs and availability of GSH. GSH decreases in association with risk factors for disease and undergoes a diurnal variation with lowest values beginning in the morning and extending through midday. Decreased GSH has been associated with specific diseases, including cardiovascular disease and diabetes, and has been implicated in many others. Abundant biochemical data support a direct causal link between low GSH, impaired defenses, and cellular susceptibility in model systems. Emerging personalized health strategies utilize GSH as a quantitative indicator of health with the expectation that diet selection, GSH supplementation, and lifestyle approaches can be used to manage GSH status, thereby providing a health dividend by protecting against disease development.

Introduction
More than 100 years of research and 81,000 scientific papers have established glutathione (GSH) as one of the most important protective molecules in the human body. The present article provides a brief overview of GSH and its functions in health and disease. Low GSH has been implicated in neuronal, hepatic, renal, pulmonary, cardiac, musculoskeletal, pancreatic, gastrointestinal, visual, auditory, and infectious diseases. Accumulating data have established that poor diet and age-related disease can create a functional disparity between the body’s natural GSH defenses and the levels needed for optimal health. The purpose of this article is to provide practical considerations for health professionals concerning the evolving use of GSH as a strategy for maintenance of health.

What is Glutathione?
GSH is a component of defenses for both acute and chronic health challenges. Acute deficiency can be caused by exposure to toxic chemicals and endogenous oxidative reactions. Under acute GSH deficiency, cells cannot maintain normal cell functions, lose ability to divide normally, and can undergo either necrotic or apoptotic cell death. Under chronic conditions, variations in GSH levels occur due to nutrition, environmental exposures, and activation of the immune system. These variations affect risk of chronic and age-related diseases by limiting protective functions. The protective functions include elimination of cancer-causing chemicals, enhancement of antioxidant defenses, and maintenance of homeostatic conditions of the epithelial barriers. GSH protects against hundreds of cancer-causing chemicals. GSH is at the apex of a group of protective chemicals, including vitamins C and E, which guard against oxidative damage to tissues. Interorgan transport of GSH is part of a homeostatic control system3 that maintains a “redox” environment essential for life. The term “redox” refers to chemical reactions involving electron transfer. Adenosine triphosphate (ATP) is obtained from redox reactions in the mitochondria. In this process, most electron transfer occurs with reduction of O2 to water, but a small fraction is reduced to hydrogen peroxide and toxic oxygen radical species. GSH is critical for elimination of these oxidants.